A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM-3)

被引：0

作者：

Weisel, Katja ^{[1
]}

Hungria, Vania T. M. ^{[2
]}

Radinoff, Atanas ^{[3
]}

Delimpasi, Sosana ^{[4
]}

Gabor, Mikala ^{[5
]}

Masszi, Tamas ^{[6
]}

Li, Jian ^{[7
]}

Capra, Marcelo ^{[8
]}

Matsumoto, Morio ^{[9
]}

Sule, Neal ^{[10
]}

Li, Mary ^{[10
]}

McKeown, Astrid ^{[11
]}

He, Wei ^{[12
]}

Bright, Shelley ^{[10
]}

Currie, Brooke ^{[13
]}

Boyle, Julia ^{[14
]}

Opalinska, Joanna ^{[10
]}

Dimopoulos, Meletios Athanasios ^{[15
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[2] Dept Hematol, Clin Sao Germano, Sao Paulo, Brazil

[3] Univ Hosp St Ivan Rilski EAD, Sofia, Bulgaria

[4] Gen Hosp Evangelismos, Athens, Greece

[5] Natl Inst Haematol & Infect Dis, South Pest Cent Hosp, Budapest, Hungary

[6] Semmelweis Univ, Dept Internal Med & Haematol, Budapest, Hungary

[7] Chinese Acad Med Sci & Peking Union Med Coll, Dept Hematol, Peking Union Med Coll Hosp, Beijing, Peoples R China

[8] Hosp Mae Deus, Ctr Integrado Hematol & Oncol, Porto Alegre, RS, Brazil

[9] Natl Hosp Org, Shibukawa Med Ctr, Shibukawa, Japan

[10] GSK, Upper Providence, PA USA

[11] GSK, Stevenage, Herts, England

[12] GSK, Waltham, MA USA

[13] GSK, Rockville, MD USA

[14] GSK, London, England

[15] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

multiple myeloma; belantamab mafodotin; relapsed/refractory multiple myeloma; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-509

引用

页码：S504 / S505

页数：2

共 50 条

[31] MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM)
San-Miguel, Jesus F.
Weisel, Katja C.
Moreau, Philippe
Lacy, Martha
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Banos, Anne
Rocafiguera, Albert Oriol
Yu, Xin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[32] KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma
Mateos, M. V.
Blacklock, H.
Rocafiguera, A. O.
Iida, S.
Jagannath, S.
Lonial, S.
Kher, U.
Farooqui, M.
Marinello, P.
San-Miguel, J.
ANNALS OF ONCOLOGY, 2016, 27
[33] Safety and tolerability of single-agent belantamab mafodotin (Belamaf; GSK2857916) in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Pooled data from DREAMM-1 and DREAMM-2
Kortuem, M.
Trudel, S.
Cohen, A. D.
Richardson, P. G.
Lonial, S.
Opalinska, J. B.
Gupta, I
Byrne, J.
Zhi, E.
Baron, J.
Morgan, L.
Voorhees, P. M.
Popat, R.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 97 - 98
[34] Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM)
Suvannasankha, Attaya
Kapetanakis, Venediktos
Prawitz, Thibaud
Sarri, Grammati
Hughes, Rachel
Wang, Feng
Hogea, Cosmina
Ferrante, Shannon Allen
Gorsh, Boris
Willson, Jenny
Popat, Rakesh
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S300 - S301
[35] Matching-adjusted indirect comparisons (MAIC) of safety between single-agent belantamab mafodotin versus selinexor plus dexamethasone in relapsed/refractory multiple myeloma (RRMM)
Suvannasankha, A.
Prawitz, T.
Kapetanakis, V.
Sarri, G.
Hughes, R.
Wang, F.
Hogea, C.
Ferrante, S. Allen
Gutierrez, B.
Gorsh, B.
Willson, J.
Popat, R.
ANNALS OF ONCOLOGY, 2020, 31 : S654 - S654
[36] DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).
Mateos, Maria-Victoria
Robak, Pawel
Hus, Marek
Fu, Chengcheng
Zherebtsova, Vera
Ward, Christopher
Ho, P. Joy
de Almeida, Ana Carolina
Hajek, Roman
Kim, Kihyun
Dimopoulos, Meletios Athanasios
Cerchione, Claudio
Pirooz, Nicholas
McKeown, Astrid
Kazeem, Gbenga
Baig, Hena
Eccersley, Lydia
Roy-Ghanta, Sumita
Opalinska, Joanna
Hungria, Vania
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[37] DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) plus Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
Mateos, Maria Victoria
Robak, Pawel
Hus, Marek
Fu, ChengCheng
Zherebtsova, Vera
Ward, Christopher
Ho, P. Joy
De Almeida, Ana Carolina
Hajek, Roman
Kim, Kihyun
Dimopoulos, Meletios
Cerchione, Claudio
Pirooz, Nick
McKeown, Astrid
Kazeem, Benga
Baig, Hena
Eccersley, Lydia
Roy-Ghanta, Sumita
Opalinska, Joanna
Hungria, Vania
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S571 - S571
[38] A Phase 3 randomized, open-label trial of selinexor, pomalidomide, and dexamethasone versus elotuzumab, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma
Weisel, Katja
Bentur, Ohad
Van Domelen, Dane
Boccadoro, Mario
Sonneveld, Pieter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S216 - S217
[39] Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study
Ocio, E. M.
Shah, J.
Jagannath, S.
Mateos, M-V
Palumbo, A.
Kher, U.
Marinello, P.
San Miguel, J.
ANNALS OF ONCOLOGY, 2016, 27
[40] DREAMM-2: Assessing efficacy via indirect comparison of single-agent belantamab mafodotin versus selinexor plus dexamethasone combination in anti-CD38 exposed relapsed/refractory multiple myeloma (RRMM).
Popat, Rakesh
Suvannasankha, Attaya
Kapetanakis, Venediktos
Prawitz, Thibaud
Sarri, Grammati
Hughes, Rachel
Wang, Feng
Hogea, Cosima
Ferrante, Shannon Allen
Willson, Jenny
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →